Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as…
1 addition to the CANSLIM scanner from @TrendSpider $GKOS https://t.co/MCmEU6JVBE
14 analysts rate GKOS Buy on consensus.
Consensus price target: $199.31 (+13.33% upside from $175.86)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Navratil Tomas CHIEF DEVELOPMENT OFFICER | Oct 5, 2026 | Sale | 312 | $51.67K |
| Navratil Tomas CHIEF DEVELOPMENT OFFICER | Oct 5, 2026 | Sale | 888 | $145.57K |
| Navratil Tomas CHIEF DEVELOPMENT OFFICER | Oct 5, 2026 | Sale | 327 | $53.88K |
| Navratil Tomas CHIEF DEVELOPMENT OFFICER | Sep 16, 2026 | Sale | 191 | $31.74K |
| Navratil Tomas CHIEF DEVELOPMENT OFFICER | Sep 16, 2026 | Sale | 234 | $40K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $507.44M | +32.33% | $-187.69M |
| 2024 | $383.48M | +21.85% | $-146.37M |
| 2023 | $314.71M | +11.26% | $-134.66M |
Stock data for GKOS: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics